| 注册
首页|期刊导航|中国药物经济学|裸花紫珠联合抗菌药物治疗细菌感染性疾病的有效性和安全性系统评价

裸花紫珠联合抗菌药物治疗细菌感染性疾病的有效性和安全性系统评价

傅健英 蔡晓东 马小花 王升勇 刘春瑶 陈凡

中国药物经济学2024,Vol.19Issue(5):74-81,89,9.
中国药物经济学2024,Vol.19Issue(5):74-81,89,9.DOI:10.12010/j.issn.1673-5846.2024.05.013

裸花紫珠联合抗菌药物治疗细菌感染性疾病的有效性和安全性系统评价

Meta-analysis of Callicarpae Nudiflorae combined with Antibiotics in Treatment of Bacterial Infectious Disease

傅健英 1蔡晓东 1马小花 1王升勇 1刘春瑶 1陈凡1

作者信息

  • 1. 海南卫生健康职业学院药学系,海口 571000
  • 折叠

摘要

Abstract

Objective To evaluate the effectiveness and safety of callicarpae nudiflorae combined with antibiotics in treatment of bacterial infectious disease,in order to provide basis for evidence-based in the rationality of the combination.Methods PubMed,EMBase,Cochrane library,CNKI,VIP and Wanfang database were researched from inception to May 2022.Meta-analysis was performed by using RevMan 5.3 software.Results A total of 23 clinical controlled trials were included.Meta-analysis showed that total response rate[RR=1.20,95%CI(1.14~1.26),P<0.000 01],antipyretic time[MD=-2.13,95%CI(-3.45~-0.80),P=0.002],WBC[MD=0.77,95%CI(0.01~1.52),P=0.05],PCT[MD=1.14,95%CI(0.50~1.78),P=0.000 5],CRP[MD=1.44,95%CI(0.91~1.97),P<0.000 01],IL-6[MD=0.97,95%CI(0.04~1.90),P=0.04]of experiment group were better than those of control group.Fourteen trials were included outcome indicators of adverse reactions.From the results of meta-analysis,experiment group was same to the control group in the incidence of adverse drug reaction without statistical difference[RR=0.91,95%CI(0.58~1.43),P=0.69].Conclusion The combined antibacterial drugs can significantly improve the total effective rate of the treatment of bacterial infectious diseases,shorten the fever time,and reduce the levels of WBC,PCT,CRP and IL-6,and there is no significant difference in the incidence of adverse reactions between the two groups.

关键词

裸花紫珠/抗菌药物/细菌感染性疾病/Meta分析

Key words

Callicarpae nudiflorae/Antibiotics/Bacterial infectious disease/Meta-analysis

分类

医药卫生

引用本文复制引用

傅健英,蔡晓东,马小花,王升勇,刘春瑶,陈凡..裸花紫珠联合抗菌药物治疗细菌感染性疾病的有效性和安全性系统评价[J].中国药物经济学,2024,19(5):74-81,89,9.

中国药物经济学

1673-5846

访问量0
|
下载量0
段落导航相关论文